for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Quest Diagnostics Inc

DGX.N

Latest Trade

128.39USD

Change

-0.47(-0.36%)

Volume

337,860

Today's Range

128.14

 - 

130.76

52 Week Range

85.43

 - 

134.63

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Quest Diagnostics - CEO Stephen Rusckowski's FY 2020 Total Compensation Was $14.1 Mln

April 9 (Reuters) - Quest Diagnostics Inc <DGX.N>::QUEST DIAGNOSTICS SAYS CEO STEPHEN RUSCKOWSKI 'S TOTAL COMPENSATION FOR FY2020 WAS $14.1 MILLION VERSUS $10.1 MILLION IN FY2019 - SEC FILING.QUEST DIAGNOSTICS SAYS FOR 2020, MEDIAN IDENTIFIED EMPLOYEE TO CEO PAY RATIO WAS ESTIMATED TO BE ABOUT 1 TO 197.

Iqvia Acquires Remaining Interest In Q2 Solutions From Quest Diagnostics

April 1 (Reuters) - Iqvia Holdings Inc <IQV.N>::IQVIA ACQUIRES REMAINING INTEREST IN Q2 SOLUTIONS FROM QUEST DIAGNOSTICS; RAISES FULL YEAR 2021 ADJUSTED DILUTED EPS GUIDANCE.ANNOUNCED ACQUISITION OF 40 PERCENT MINORITY SHARE OF Q(2) SOLUTIONS FROM QUEST DIAGNOSTICS FOR $760 MILLION.TRANSACTION HAS BEEN FINANCED THROUGH CASH ON HAND.TRANSACTION IS NOT EXPECTED TO IMPACT IQVIA'S TARGET NET LEVERAGE RATIO.TRANSACTION IS EXPECTED TO BE APPROXIMATELY $0.12 ACCRETIVE TO IQVIA'S 2021 ADJUSTED DILUTED EPS.TRANSACTION IS EXPECTED TO BE AT LEAST $0.18 ACCRETIVE TO 2022 ADJUSTED DILUTED EPS.SEES 2021 ADJUSTED DILUTED EPS $7.89 - $8.20.FY2021 EARNINGS PER SHARE VIEW $7.98 -- REFINITIV IBES DATA.

Zora Biosciences Licenses Ceramide Technology To Quest Diagnostics For Cardiovascular Mortality Prediction Test

March 15 (Reuters) - Quest Diagnostics Inc <DGX.N>::ZORA BIOSCIENCES LICENSES CERAMIDE TECHNOLOGY TO QUEST DIAGNOSTICS FOR CARDIOVASCULAR MORTALITY PREDICTION TEST.QUEST - EXPECTS TO BEGIN TO OFFER NEW TEST SERVICE IN U.S. THROUGH ITS CARDIOMETABOLIC CENTER OF EXCELLENCE AT CLEVELAND HEARTLAB AS SOON AS NEXT YEAR.QUEST -PLANS TO DEVELOP TEST SERVICE BASED ON ZORA'S CERAMIDE TECH AS AN AID IN IDENTIFYING PATIENTS AT RISK FOR CARDIOVASCULAR-RELATED DISEASE, DEATH.

Quest Diagnostics Says COVID-19 Testing Revenues Are Expected To Step Down In 2022

March 11 (Reuters) - Quest Diagnostics Inc <DGX.N>::QUEST DIAGNOSTICS - COVID-19 TESTING REVENUES ARE EXPECTED TO STEP DOWN MEANINGFULLY IN 2022 - FILING.QUEST DIAGNOSTICS - BASE BUSINESS REVENUES (WHICH EXCLUDES COVID-19 TESTING) ARE EXPECTED TO FULLY RECOVER BY END OF 2021.

Quest Diagnostics Says Will Repurchase $900 Mln Shares In First Half Of 2021

March 11 (Reuters) - Quest Diagnostics Inc <DGX.N>::QUEST DIAGNOSTICS INC - COMPANY TO REPURCHASE $900 MILLION OF ITS SHARES IN FIRST HALF OF 2021.QUEST DIAGNOSTICS INC - OUTLOOK FOR FIRST HALF OF 2021 REMAINS UNCHANGED.QUEST DIAGNOSTICS - COVID-19 TESTING IS EXPECTED TO CONTINUE INTO 2022 AT LOWER LEVELS.QUEST DIAGNOSTICS INC - INVIGORATE SAVINGS OF 3% ANNUALLY EXPECTED TO CONTINUE.QUEST DIAGNOSTICS - PROVIDED COMPOUND ANNUAL GROWTH RATE PROJECTION FOR 2022 TO 2024 OF 7-9% FOR ADJUSTED DILUTED EPS, WHICH IS A NON-GAAP MEASURE.QUEST DIAGNOSTICS - RAISED LONG-TERM OUTLOOK TO A 4-5% REVENUE CAGR FOR BASE BUSINESS AND A 7-9% EARNINGS CAGR FOR TOTAL COMPANY.

Quest Diagnostics Introduces New Covid-19 Semi-Quantitative Serology Test Service

Feb 24 (Reuters) - Quest Diagnostics Inc <DGX.N>::QUEST DIAGNOSTICS INTRODUCES NEW COVID-19 SEMI-QUANTITATIVE SEROLOGY TEST SERVICE.QUEST DIAGNOSTICS- TEST SERVICE PROVIDES POSITIVE/NEGATIVE RESULT, NUMERICAL RESULT THAT MAY GIVE BASIS FOR ASSESSING CHANGES IN ANTIBODY BLOOD LEVELS.QUEST DIAGNOSTICS INC - NEW SERVICE CAN AID IN ASSESSING BLOOD LEVELS OF ANTIBODIES PRODUCED TO STRUCTURAL PROTEINS OF SARS-COV-2 SPIKE PROTEIN.QUEST DIAGNOSTICS INC - TEST MAY AID IN INDICATING AN IMMUNE RESPONSE RESULTING FROM A RECENT OR PRIOR INFECTION OR VACCINATION.QUEST DIAGNOSTICS INC - TEST WILL NOT DIFFERENTIATE BETWEEN IMMUNE RESPONSE MOUNTED IN RESPONSE TO INFECTION OR VACCINATION..

Quest Diagnostics Reports Board Leadership Changes

Feb 23 (Reuters) - Quest Diagnostics Inc <DGX.N>::QUEST DIAGNOSTICS ANNOUNCES BOARD LEADERSHIP CHANGES.QUEST DIAGNOSTICS INC - DANIEL C. STANZIONE TO RETIRE FROM BOARD AND AS LEAD INDEPENDENT DIRECTOR.QUEST DIAGNOSTICS INC - DANIEL C. STANZIONE TO RETIRE FROM BOARD AND AS LEAD INDEPENDENT DIRECTOR.QUEST DIAGNOSTICS INC - TIMOTHY M. RING SELECTED NEW LEAD INDEPENDENT DIRECTOR.QUEST DIAGNOSTICS INC - VICKY B. GREGG SELECTED CHAIR, COMPENSATION COMMITTEE.QUEST DIAGNOSTICS INC - VICKY B. GREGG SELECTED CHAIR, COMPENSATION COMMITTEE.

Quotient Limited Announces Manuel Mendez As Chief Executive Officer

Feb 23 (Reuters) - Quotient Ltd <QTNT.O>::QUOTIENT LIMITED ANNOUNCES MANUEL MENDEZ AS CHIEF EXECUTIVE OFFICER.QUOTIENT LTD - FRANZ WALT, WHO HAS SERVED AS COMPANY'S CEO SINCE 2018 IS RETIRING.QUOTIENT LTD - MANUEL JOINS QUOTIENT FROM QUEST DIAGNOSTICS WHERE HE SERVED AS SENIOR VICE PRESIDENT & CHIEF COMMERCIAL OFFICER.

Quest Diagnostics Increases Dividend 10.7% To $0.62 Per Quarter

Feb 4 (Reuters) - Quest Diagnostics Inc <DGX.N>::QUEST DIAGNOSTICS INCREASES DIVIDEND 10.7% TO $0.62 PER QUARTER; ANNOUNCES $1 BILLION INCREASE IN SHARE REPURCHASE AUTHORIZATION.QUEST DIAGNOSTICS INC - WITH INCREASE, ANNUAL DIVIDEND WILL BE $2.48 PER SHARE.QUEST DIAGNOSTICS INC - INCREASED REPURCHASE AUTHORITY IS IN ADDITION TO $917 MILLION THAT WAS AVAILABLE AS OF DECEMBER 31, 2020.

Quest Diagnostics Raises Outlook For Full Year 2020

Dec 16 (Reuters) - Quest Diagnostics Inc <DGX.N>::QUEST DIAGNOSTICS RAISES OUTLOOK FOR FULL YEAR 2020.REVENUES FOR FULL YEAR 2020 EXPECTED TO BE AT LEAST $9.35 BILLION .SEES FY 2020 ADJUSTED EARNINGS PER SHARE AT LEAST $10.75.SEES FY 2020 EARNINGS PER SHARE AT LEAST $9.98.CASH PROVIDED BY OPERATIONS FOR FULL YEAR 2020 EXPECTED TO BE AT LEAST $1.95 BILLION.FY2020 EARNINGS PER SHARE VIEW $10.16, REVENUE VIEW $9.10 BILLION -- REFINITIV IBES DATA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up